Actavis, a pharmaceutical firm recently acquired by Watson Pharmaceuticals, Inc., has donated $200,000 worth of medicines to help Hurricane Sandy victims in New York and New Jersey. AmeriCares delivered antibiotics, pediatric medicines and other Actavis products to healthcare providers assisting families impacted by the storm within days of the disaster.
“Actavis responded swiftly and generously to meet the medical needs of storm victims,” says Geoff Kneisel, AmeriCares’ vice president of corporate relations. “The company’s donations were an amazing help, and were immediately delivered to healthcare providers and first responders in the most devastated areas.”
AmeriCares relief workers have been working nonstop since Sandy struck, providing $2.3 million in aid benefitting nearly 300,000 storm victims in New York, New Jersey, and Connecticut. To date, AmeriCares has delivered 110 aid shipments for affected families in the hardest hit communities and awarded over $750,000 in grants to health clinics and partner organizations helping storm victims. (One shipment heading out soon after Hurricane Sandy is shown here.) The humanitarian aid organization also deployed its 40-ft mobile clinic to New York City to assist healthcare facilities unable to treat patients because of storm damage and power outages.
Actavis has partnered with AmeriCares for more than 20 years, donating more than $170 million in aid to 83 countries.
AmeriCares is a nonprofit global health and disaster relief organization that delivers medicines, medical supplies, and aid to people in need around the world and across the U.S. Since it was established in 1982, AmeriCares has distributed more than $10 billion in humanitarian aid to 164 countries.
The combined Watson and Actavis are a global, integrated specialty pharmaceutical company focused on developing, manufacturing, and distributing generic, brand, and biosimilar products. The Company has global and U.S. headquarters in Parsippany, NJ, with international headquarters in Zug, Switzerland.
Watson and Actavis describe the company as the world's third-largest generics prescription drug manufacturer, with more than 750 products marketed globally through operations in more than 60 countries. Watson’s global branded pharmaceutical business develops and markets products principally in urology and women's health, and is committed to developing and marketing biosimilars products in women’s health, oncology, and other therapeutic categories. In addition, Watson is the fourth-largest U.S. generic pharmaceutical product distributor through its Anda, Inc. business, and also develops and out-licenses generic pharmaceutical products outside of the U.S. through its Medis third-party business.
![“Another key [UDI] benefit, because we're calling that product by the same name across the healthcare supply chain… rich and robust data that we can access around supply consumption and utilization rates. One of the buzz terms we've heard during the COVID-19 crisis was what's my burn rate? How fast am I going through gowns, masks, gloves?” – Mike Schiller, Senior Director at AHRMM](https://img.healthcarepackaging.com/files/base/pmmi/all/image/2020/08/UDI.5f4d326e41d53.png?auto=format&fit=crop&h=146&w=340)
